cronos group glp-1 receptor agonist weight management diabetes treatments Oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies How GLP-1 Receptor Agonists Evolved

Because a significant portion of oral carnitine remains unabsorbed in the gastrointestinal tract, it interacts heavily with the gut microbiome

(The FDA has approved some GLP-1 drugs only for diabetes treatment, but they are often prescribed off-label for obese patients without diabetes.) The Downsides of GLP-1's However, GLP-1 medications can cause side effects

This work was supported by a grant of the Ministry of Research, Innovation and Digitization, under the Romanias National Recovery and Resilience Plan funded by EU Next Generation EU program, project Artificial intelligence-powered personalized health and genomics libraries for the analysis of long-term effects in COVID-19 patients (AI-PHGL-COVID) number 760073/23.05.2023, code 285/30.11.2022, within Pillar III, Component C9, Investment 8 and by a grant of the Ministry of Research, Innovation and Digitization, CNCS, UEFISCDI, project number PN-III-Pl-1.1-PD-2021-0273, within PNCDI III

Conversely, metabolic dysregulation can contribute to the severity of multiple disease conditions including autoimmunity, alloimmunity, and cancer